Question: <span style="color: red; font-weight: bold; font-size:22px">How does Cancer affect disease?</span> <p>=================================================<br><span style="color: black; font-weight: bold">Title: Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants<br>Score: 11.624551773071289<br>Date: 2021-02-15<br>Source: Medline; PMC<br></span>CONCLUSIONS: Patients with cancer were more susceptible to COVID-19. As a risk factor, cancer increased <span style="color: green; font-weight: bold">mortality</span> among COVID-19 patients. Among COVID-19 patients with cancer, those who had lung cancer had a higher <span style="color: green; font-weight: bold">mortality</span> than those without lung cancer. Our findings suggested that clinicians should pay more attention to cancer patients diagnosed with COVID-19 and provide useful information for their clinical management.</p> <p>=================================================<br><span style="color: black; font-weight: bold">Title: SARS-CoV-2 Infection in Cancer Patients: Effects on Disease Outcomes and Patient Prognosis<br>Score: 10.129552841186523<br>Date: 2020-11-05<br>Source: Medline; PMC<br></span>SARS-CoV-2 infection on cancer patients. ABSTRACT: The severity of coronavirus disease 2019 (COVID-19) symptoms and outcomes vary immensely among patients. Predicting disease progression and managing disease symptoms is even more challenging in cancer patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Cancer therapies, including chemotherapy, radiotherapy, and immunotherapy, often <span style="color: green; font-weight: bold">suppress the immune system</span>, rendering cancer patients </p> <p>=================================================<br><span style="color: black; font-weight: bold">Title: COVID-19 and Cancer:Current Challenges and Perspectives<br>Score: 10.034786224365234<br>Date: 2020-10-01<br>Source: Elsevier; Medline; PMC<br></span>he treatment of patients with cancer during the pandemic. We additionally discuss the potential long-lasting impact of the pandemic on cancer care, due to its <span style="color: green; font-weight: bold">deleterious effect on cancer research</span>, as well as biological insights from the cancer research community that could help develop novel therapies for all patients with COVID-19.</p> Question: <span style="color: red; font-weight: bold; font-size:22px">How does Cerebrovascular disease affect disease?</span> <p>=================================================<br><span style="color: black; font-weight: bold">Title: A case series of ischemic stroke with coronavirus disease 2019 in two Egyptian centers<br>Score: 8.82690715789795<br>Date: 2020-12-24<br>Source: Medline; PMC<br></span>andemic. CASE PRESENTATION: We are presenting 10 cases with cerebrovascular manifestations after having COVID-19 few days prior to stroke. CONCLUSION: Cerebrovascular manifestations can occur in association with COVID-19 and may have significant implications on <span style="color: green; font-weight: bold">prognosis and management</span>.</p> <p>=================================================<br><span style="color: black; font-weight: bold">Title: Impact of Cerebrovascular and Cardiovascular Diseases on Mortality and Severity of COVID-19 â€“ Systematic Review, Meta-analysis, and Meta-regression<br>Score: 7.584205627441406<br>Date: 2020-05-14<br>Source: Elsevier; Medline; PMC<br></span>92, 2.96], p<0.001; I(2): 0%) and was borderline significant for severe COVID-19 (RR 1.88 [1.00, 3.51], p=0.05; I(2): 87%). Cardiovascular disease was associated with <span style="color: green; font-weight: bold">increased composite poor outcome</span> (RR 2.23 [1.71, 2.91], p<0.001; I(2): 60%), and its mortality (RR 2.25 [1.53, 3.29], p<0.001; I(2): 33%) and severe COVID-19 (RR 2.25 [1.51, 3.36], p<0.001; I(2): 76%) subgroup. Me</p> <p>=================================================<br><span style="color: black; font-weight: bold">Title: The association of cerebrovascular disease with adverse outcomes in COVID-19 patients: a meta-analysis based on adjusted effect estimates<br>Score: 6.855110168457031<br>Date: 2020-08-28<br>Source: Elsevier; Medline; PMC<br></span><span style="color: green; font-weight: bold">re likelihood to progress fatal outcomes</span> than patients without a history of cerebrovascular disease (pooled effect = 1.78, 95% CI: 1.04-3.07). CONCLUSION: This study for the first time indicated that cerebrovascular disease was an independent risk factor for predicting the adverse outcomes, particularly fatal outcomes, in COVID-19 patients on the basis of adjusted effect estimates. Well-designed studies with larger sample size are needed for further verification.</p>,time: 0.8583s